ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Oncolytics Biotech Inc. (ONCY) Report Updated: Apr 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Oncolytics Biotech Inc. (ONCY)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Biotechnology
Competitors: ANAC, ATNM, INSY, BCRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: F down downgrade
Last Week: D same upgrade
Two Weeks Ago: F up downgrade
service keys

Oncolytics Biotech Inc.© quotemedia

Company Profile

Oncolytics Biotech Inc., a biotechnology company, focuses on the development of oncolytic viruses as potential cancers therapeutics. The company develops REOLYSIN, a human cancer therapeutic. Its clinical program includes various human trials comprising a Phase III clinical trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Recent News: Oncolytics Biotech Inc.